70938 Federal Register / Vol. 65, No. 229 / Tuesday, November 28, 2000 / Notices

The firm plans to bulk manufacture

amphetamine for a customer and to bulk

manufacture the phenylacetone for the

manufacture of the amphetamine. The

bulk 2,5-dimethoxyamphetamine will

be used for conversion into a noncontrolled substance.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substance

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than January

29, 2001.

Dated: November 14, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–30295 Filed 11–27–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances;

Notice of Registration

By Notice dated April 25, 2000, and

published in the Federal Register on

May 2, 2000, (65 FR 30615), Lipomed,

Inc., One Broadway, Cambridge,

Massachusetts 02142, made application

to the Drug Enforcement Administration

(DEA) to be registered as an importer of

the basic classes of controlled

substances listed below:

Drug Schedule

Cathinone (1235) .......................... I

Methaqualone (2565) ................... I

Lysergic acid diethylamide (7315) I

Marihuana (7360) ......................... I

Tetrahydrocannabinols (7370) ..... I

mescaline (7381) .......................... I

3,4,5-Trimethoxyamphetamine

(7390).

I

4-Bromo-2,5-

dimethoxyamphetamine (7391).

I

4-Methyl-2,5-

dimethoxyamphetamine (7395).

I

2,5-Dimethoxyamphetamine

(7396).

I

2,5-Dimethoxy-4-

ethylamphetamine (7399).

I

3,4-Methylenedioxyamphetamine

(7400).

I

3,4-Methylenedioxy-Nethylamphetamine (7404).I

Drug Schedule

3,4-

Methylenedioxymethamphetamine (7405).

I

Psilocybin (7437) .......................... I

Psilocyn (7438) ............................. I

Acetyldihydrocodeine (9051) ........ I

Dihydromorphine (9145) ............... I

Heroin (9200) ............................... I

Tilidine (9750) ............................... I

Amphetamine (1100) .................... II

Methamphetamine (1105) ............ II

Amobarbital (2125) ....................... II

Secobarbital (2315) ...................... II

Phencyclidine (7471) .................... II

Cocaine (9041) ............................. II

Codeine (9050) ............................. II

Dihydrocodeine (9120) ................. II

oxycodone (9143) ......................... II

Hydromorphone (9150) ................ II

Benzoylecgonine (9180) ............... II

Hyddrocodone (9193) ................... II

Levorphanol (9220) ...................... II

Methadone (9250) ........................ II

Dextropropoxyphene, bulk (nondosage forms) (9273).II

Morphine (9300) ........................... II

Thebaine (9333) ........................... II

oxymorphone (9652) .................... II

Alfentanil (9737) ........................... II

Fentanyl (9801) ............................ II

The firm plans to import small

reference standard quantities of finished

commercial product from its sister

company in Switzerland for sale to its

customers for drug testing and

pharmaceutical research and

development.

No comments or objections have been

received. DEA has considered the

factors in title 21, United States Code,

section 823(a) and determined that the

registration of Lipomed, Inc. to import

the listed controlled substances is

consistent with the public interest and

with United States obligations under

international treaties, conventions, or

protocols in effect on May 1, 1971, at

this time. DEA has investigated

Lipomed, Inc. on a regular basis to

ensure that the company’s continued

registration is consistent with the public

interest. These investigations have

included inspection and testing of the

company’s physical security systems,

audits of the company’s records,

verification of the company’s

compliance with state and local laws,

and a review of the company’s

background and history. Therefore,

pursuant to section 1008(a) of the

Controlled Substances Import and

Export Act and in accordance with title

21, Code of Federal Regulations, section

1311.42, the above firm is granted

registration as an importer of the basic

classes of controlled substances listed

above.

Dated: November 6, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–30290 Filed 11–27–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to section 1008 of the

controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with section

1301.34 of title 21 Code of Federal

Regulations (CFR), notice is hereby

given that on April 18, 2000, Research

Triangle Institute, Kenneth H. Davis, Jr.,

Hermann Building, East Institute Drive,

P.O. Box 12194, Research Triangle Park,

North Carolina 27709, made application

to the Drug Enforcement Administration

to be registered as an importer of the

basic classes of controlled substances

listed below:

Drug Schedule

Tetrahydrocannabinols (7370) ..... I

Cocaine (9041) ............................. II

The firm plans to import small

quantities of the listed controlled

substances for the National Institute of

Drug Abuse and other clients.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of these basic classes of

controlled substances may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections or

requests for a hearing may be addressed,

in quintuplicate, to the deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, DC

20537, Attention: DEA Federal Register